DY
ALBO

Dowling & Yahnke’s Albireo Pharma Inc ALBO Stock Holding History

Dowling & Yahnke’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,135
Closed -$175K – 276
2014
Q1 		$175K Hold
2,135
– – 0.02% 269
2013
Q4 		$146K Hold
2,135
– – 0.02% 246
2013
Q3 		$202K Buy
2,135
+333
+18% +$43.4K 0.03% 229
2013
Q2 		$226K Buy
+1,802
New +$187K 0.04% 216

Other funds holding ALBO

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Dowling & Yahnke's ALBO Position: Q2 2014 in Review

Dowling & Yahnke sold out of Albireo Pharma Inc (ALBO) in Q2 2014, closing a stake of 2,135 shares — an estimated $175K sold.

Dowling & Yahnke first reported a position in ALBO in Q2 2013 and held it in 4 quarters. The position peaked at $226K in Q2 2013. 37 funds tracked by Wall St. Rank hold ALBO as of Q2 2014.

  • Dowling & Yahnke reported no remaining Albireo Pharma Inc position as of Q2 2014 after selling out during the quarter.
  • Dowling & Yahnke sold 2,135 Albireo Pharma Inc shares in Q2 2014, an estimated $175K.
  • Dowling & Yahnke first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 4 quarters.
  • Dowling & Yahnke's Albireo Pharma Inc position peaked at $226K in Q2 2013.
  • 37 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2014.

Based on Dowling & Yahnke's 13F filing for Q2 2014, filed 15 Aug 2014.